Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01265394 · ClinicalTrials.gov registry record · Phase 3
Positron Emission Tomography (PET) Amyloid Imaging of the Brain in Healthy Young Adult Subjects
A Phase 3 study, sponsored by GE Healthcare.
- Completed
- Registry status
- Phase 3
- Development phase
- 218
- Enrollment target
NCT01265394 is a Phase 3 study that has completed, run by GE Healthcare. The registered enrollment target is 218 participants.
The verdict
NCT01265394, a Phase 3 study, has completed, sponsored by GE Healthcare.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 218 participants
- Enrollment target
Study Summary
Amyloid is an abnormal chemical found in the brain of patients with Alzheimer's Disease (AD). The study drug helps produce pictures of amyloid in the brain. The purpose of this study is to determine how well the study drug performs in young healthy subjects.
Interventions
- DRUG [18F] Flutemetamol
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 218 participants |
| Start Date | 2010-12 |
| Est. Completion | 2011-04 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01265394
The ClinicalTrials.gov registry entry for NCT01265394 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 218 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is GE Healthcare, which has 99 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which [18F] Flutemetamol is the first listed.
NCT01265394 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01265394 about?
NCT01265394 is a clinical study titled "Positron Emission Tomography (PET) Amyloid Imaging of the Brain in Healthy Young Adult Subjects". Amyloid is an abnormal chemical found in the brain of patients with Alzheimer's Disease (AD). The study drug helps produce pictures of amyloid in the brain. The purpose of this study is to determine how well the study drug performs in young healthy subjects.
What is the current status of trial NCT01265394?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 218 participants. The study started on 2010-12. Estimated completion is 2011-04.
What interventions are being tested in trial NCT01265394?
The interventions under investigation include: [18F] Flutemetamol (DRUG).
Who is sponsoring clinical trial NCT01265394?
This trial is sponsored by GE Healthcare, which has 99 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.